Status:
COMPLETED
Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain
Lead Sponsor:
Endo Pharmaceuticals
Conditions:
Chronic Pain
Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.
Detailed Description
The purpose of this study is to evaluate the analgesic effectiveness and tolerability of oxymorphone ER in the treatment of cancer or neuropathic pain. Opioid-naïve subjects are gradually titrated fro...
Eligibility Criteria
Inclusion
- ≥ 18 years of age or older, with moderate to severe chronic malignant and/or neuropathic pain of at least 3 months duration and either:
- have an initial pain intensity score of greater than 4 on a 10-point scale using BPI Question 5, if sub-optimally responding to their current analgesic regimen, or
- have intolerable side effects to one or more components of their current opioid-containing analgesic regimen.
- Currently receive a stable (at least 2 weeks duration) analgesic regimen
- If female, must be practicing abstinence or using a medically acceptable form of contraception (e.g., intrauterine device, hormonal birth control, or double barrier method).
- Understand written and spoken English
- Have been informed of the nature of the study and provided written informed consent
- Additional Inclusion Criteria for Cancer Patients Only:
- Have a life expectancy of at least 12 months
- Additional Inclusion Criteria for Neuropathic Patients Only:
- Have a diagnosis of:
- post-herpetic neuralgia (PHN)
- diabetic neuropathy (DN)
- complex regional pain syndrome (CRPS)
- HIV neuropathy
- idiopathic sensory neuropathy
- traumatic peripheral neuropathy
- central neuropathic pain condition (spinal cord injury, post-stroke pain), OR
- other peripheral neuropathy (upon mutual agreement of the sponsor and investigator).
Exclusion
- Have a positive pregnancy test (females only)
- Have a history of or active asthma or emphysema
- Have clinically significant hepatic impairment
- Have a history of alcohol or substance abuse within the last 3 years
- Have a history of opioid abuse within 6 months prior to study entry
- Have a known allergy or significant reaction to opioids, including codeine
- Have a known oxymorphone sensitivity or allergy
- Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT00911261
Start Date
August 1 2003
End Date
May 1 2005
Last Update
February 15 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.